Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The movement toward measuring patient outcomes resulting from a specific drug therapy, especially in an environment increasingly focused on specialty medicines, has caused researchers to look at different datasets than previously analyzed. Two patient-based datasets in particular come to mind: 1.) electronic health records (EHR), and 2.) claims data. These two data sources will each be suited to ...

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also altered assumptions by business executives about the relationship between recessions and biopharma industry drug demand. This white paper explores three questions about the future relationship of economic recessions to ...

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service researchers, biopharma industry representatives, and healthcare professionals. However, the “quick and easy fix” option of price controls invariably comes up. While this option is publicly appealing, the question is what (if ...

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about the sustainability of increasing sales revenue mainly through pricing. Further, given the cost of newer specialty medicines, performance-based pharmaceutical pricing contracts through payers will become the norm. The ...

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind squirrel? This approach, while getting lucky a few times, is a poor recipe for sustained business success given the highly complex life sciences environment that now confronts senior executives and operational leaders. ...

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to physicians in all settings. With very few exceptions, the prevailing narrative has gone unchallenged. This paper provides a more in-depth and balanced look into the evidence supporting the current narrative and ...

There is a growing importance of maintaining sales rep-physician relationships and accounting for their disruption in sales force optimization and territory alignment analyses. This will become even more crucial as the industry increasingly moves toward launching specialty medicines and major changes occur in the environmental landscape affecting pharma outcomes in sales force strategy and ...

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipeline productivity, and sustain a ROI on R&D spending needed for long-term drug development and commercial success. This means companies must look beyond current applications of commercial analytics focused mainly on ...

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in ...